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patients (16,7%) had previous PTMC, quarter of patients were in atrial
ﬁbrillation, all patients were symptomatic. Mitral valve area increased
from 1.05þ/-0.26 cm2 to 2.02þ/-0.45 cm2 (p<0.0001). Mean gradient
decreased from 13.52þ/-5.09 mmHg to 5.38 þ/- 3.15 mmHg (p<0.0001).
There was a signiﬁcant decrease in systolic pulmonary artery pressure
from 38.13þ/-7,55 mmHg to 28,25þ/-4.65mmHg (p¼0.006). Pulmonary
resistance measured by echocardiography using Tricuspid regurgita-
tion Vmax / Tricuspid VTI ratio dropped from 0.140þ/-0.017 to
0.116þ/- 0.015 (p¼0.023). Tricuspid annular point systolic excursion
(TAPSE) increased from 21.58þ/-3.08mm to 24.25þ/-4.80mm
(p¼0.029) then to 24.10þ/-5.28mm (p¼0.091) and to 24.10þ/-5.28mm
(p ¼0.091). Systolic velocity (S’) at lateral tricuspid annulus increased
from 12.80þ/-3.76cm to 14.90þ/-3.98cm (p¼0.004) and to 14.80þ/-
3.79cm (p¼0.015) then to 15.60þ/-3.92cm (p¼0.001). Tei index
decreased from 0.359þ/-0.222 to 0.207þ/-0.095 (p¼0.026) and to
0.203þ/-0.089 (p¼0.024) then to 0.201þ/-0.086 (p¼0.014). Myocar-
dial acceleration during isovolumic contraction (IVA) increased from
0.410þ/-0.106 m/s2 (p¼0.027) to 0.568þ/-0.256 m/s2 and to 0.570þ/-
0.218 m/s2 (p¼0.010) then to 0.615þ/-0.231 m/s2 (p¼0.003) respec-
tively at baseline, 24h, one month and three months after PTMC.
There was no signiﬁcant fraction area change and dp/dt ratio of the
right ventricle immediately and at mid term after PTMC.
CONCLUSIONS We suggest that there is an immediate improvement
of right ventricular systolic function after PTMC that is maintained at
mid term follow-up. Also the fact that this tendency was conﬁrmed by
using echocardiographic parameters those are loading dependent
such TAPSE and others less loading dependent such IVA suggest that
those improvements could be independent from loading conditions.
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BACKGROUND Right ventricular dysfunction (RVdisf) is predictor of
poor outcome in patients with heart failure and valvular disease. The
aim of this study was to evaluate the impact and the evolution of
RVdisf in patients with moderate-severe functional mitral regurgita-
tion (FMR) after MitraClip.
METHODS From October 2008 to July 2014, 60 consecutive high
surgical risk patients were treated and stratiﬁed into two groups:
RVdysf-group (TAPSE <16 mm and/or S’TDS <10 cm/sec, 21 patients)
and No-RVdysf-group (38 patients).
RESULTS The overall mean age was 738 (83% male). Ischemic FMR
etiology was present in 67%. Mean LVEF was 3010. Between the two
groups the only signiﬁcant differences was in presence of stroke, ICD
and use of aldosterone-antagonist higher in RVdysf group. Acute
procedural success was achieved in 90%. At 6-month echocardio-
graphic follow-up signiﬁcant improvement of RV function was
observed in all patients and was driven by only the results of patients
with RVdysf (TAPSE 153.0 vs. 194.5, p¼0.007; S’ TDI 71.2 vs.
112.8, p<0.0001; baseline vs. 6-month, respectively). Overall mean
follow-up was 565310 days. Mean improvement in 6-MWT was 116 m
(signiﬁcant in both groups).
CONCLUSIONS This observational study shows that patients with
RVdysf and FMR have signiﬁcant improvement of RV function after
MitraClip procedure. The presence of RVdysf was not predictor of
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BACKGROUND The risk of surgical mitral valve replacement in pa-
tients with severe mitral annular calciﬁcation (MAC) is very high due
to comorbidities and technical challenges related to calcium burden,
precluding surgery in many patients. There are few isolated reports of
successful transcatheter mitral valve replacement (TMVR) with
balloon expandable valves in this patient population. We report the
ﬁrst large analysis from a global registry of TMVR in MAC.
METHODS 44 patients in 17 centers from 8 different countries un-
derwent TMVR with the compassionate use of SAPIEN (Edwards
Lifesciences, Irvine, CA) valves between September of 2012 and April
of 2015.
RESULTS The mean age was 74 years (range 39-94), 71% were fe-
males, mean STS score 14.6% (range 1-29%). Most patients (91%) had
mitral stenosis and 9% mitral regurgitation. The average mean
gradient was 12 mmHg, mean area 1.04 cm2. The SAPIEN valve was
used in 11%, SAPIEN XT in 71% and SAPIEN 3 in 18% (23mm¼4.5%,
26 mm¼43.5%, 29mm¼52%). The delivery approach was transatrial in
11%, transapical in 41%, and transeptal in 48%. The valve was
implanted without embolization in 41 (93%) patients, 6 (14%) required
a second valve-in-valve (migration¼2, regurgitation¼4), and 5 (11%)
had left ventricular tract obstruction (LVOTO) with hemodynamic
